Efficacy and Safety of Celecoxib in Chinese Patients with Ankylosing Spondylitis: A 6-Week Randomized, Double-Blinded Study with 6-Week Open-Label Extension Treatment

BACKGROUND: Nonsteroidal anti-inflammatory drugs are the first-line option for treating ankylosing spondylitis (AS) in China. However, no large-scale controlled trials have been conducted in this ethnic population. OBJECTIVE: To evaluate the efficacy and safety of 6 weeks’ treatment with celecoxib i...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Feng, Gu, Jieruo, Liu, Yi, Zhu, Ping, Zheng, Yi, Fu, Jin, Pan, Sharon, Le, Shi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266770/
https://www.ncbi.nlm.nih.gov/pubmed/25516774
http://dx.doi.org/10.1016/j.curtheres.2014.08.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266770/
https://www.ncbi.nlm.nih.gov/pubmed/25516774
http://dx.doi.org/10.1016/j.curtheres.2014.08.002

Ejemplares similares